Robert Reiter, MD

Dr. Reiter is the Bing Professor of Urologic Oncology and Chief, Division of Urologic Oncology at UCLA. He is Principal Investigator on UCLA's Prostate Cancer SPORE. His research is focused on anatomical and molecular imaging of prostate cancer, as well as elucidation of the molecular mechanisms of prostate cancer progression.

Financial relationships

Attribution:
Self
Type of financial relationship:
Consultant or Advisor (Oncology)
Ineligible company:
Pfizer
Mitigation strategy:
Attest
Date reviewed:
06/13/2022
Attribution:
Self
Type of financial relationship:
Consultant or Advisor (Oncology)
Ineligible company:
Lantheus
Mitigation strategy:
Attest
Date reviewed:
06/13/2022
Attribution:
Self
Type of financial relationship:
Consultant or Advisor (Oncology)
Ineligible company:
Point biopharma
Mitigation strategy:
Attest
Date reviewed:
06/13/2022
Attribution:
Self
Type of financial relationship:
Meeting Participant or Lecturer (Oncology)
Ineligible company:
Bayer
Mitigation strategy:
Attest
Date reviewed:
06/13/2022
Attribution:
Self
Type of financial relationship:
Meeting Participant or Lecturer (Specialty Not Specified)
Ineligible company:
Genomic Health
Mitigation strategy:
Attest
Date reviewed:
06/13/2022
Attribution:
Self
Type of financial relationship:
Consultant or Advisor (Specialty Not Specified)
Ineligible company:
Janssen
Mitigation strategy:
Attest
Date reviewed:
06/13/2022
Attribution:
Self
Type of financial relationship:
Investment Interest (Specialty Not Specified)
Ineligible company:
ImaginAb Corporation
Mitigation strategy:
Attest
Date reviewed:
06/13/2022

Return to Curso en vivo de avances globales en cáncer de próstata: mejores prácticas en terapia hormonal (2022) - Espanol